nivolumab,tegafur,oxaliplatin,oteracil,gimeracil,capecitabine
ono pharma,nordic group,otsuka,bms
['nivo', 'gastric', 'nivolumab', 'esophageal', 'attraction-5', 'gastroesophageal']
attraction-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage iii (pstage iii) gastric or gastroesophageal junction (g/gej) cancer. #asco23 not met. not the same as earlier adjuvant data post trimodality for 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23